Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea
Kyungmin Huh, Wonjun Ji, Minsun Kang, Jinwook Hong, Gi Hwan Bae, Rugyeom Lee, Yewon Na, Jaehun Jung
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.12.041
Objectives: Concerns have been expressed that some drugs may increase susceptibility to SARS-CoV-2 infection. In contrast, other drugs have generated interest as potential therapeutic agents. Methods: All adults aged 18 years who were tested for COVID-19 were included. Exposure was defined as a prescription of study drugs which would have been continued until 7 days prior to test for COVID-19 or later. The outcome measures were the diagnosis of COVID-19 and severe COVID-19. Disease risk score matching and multiple logistic regression was used. Results: Matched claims and testing results were available for 219,961 subjects, of whom 7,341 (3.34%) were diagnosed with COVID-19. Patients were matched to 36,705 controls, and the subset of 878 patients of severe COVID-19 also matched with 1,927 mild-to-moderate patients. Angiotensin receptor blockers were not associated with either the diagnosis of COVID-19 (adjusted OR [aOR], 1.02; 95% confidence interval [CI], 0.90-1.15) or severe disease (aOR, 1.11; 95% CI, 0.87-1.42). The use of hydroxychloroquine was not associated with a lower risk for 0.94; 95% CI, or severe disease (aOR, 3.51; 95% CI,. Conclusions: In this national claims data-based case-control study, no commonly prescribed medications were associated with risk of COVID-19 infection or COVID-19 severity.
Conflict of interest The authors have no conflict of interest to declare.
Author contributions Drs. Huh and Jung had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Huh, Ji, Jung. Acquisition, analysis or interpretation of data: Huh, Ji, Kang, Hong, Bae, Lee, Na, Jung. Drafting of the manuscript: Huh, Ji, Jung. Statistical analysis: Huh, Kang, Na, Jung.
Appendix A. Supplementary data Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.ijid.2020.12.041.
References
Aimo, Baritussio, Emdin, Tascini, Amiodarone as a possible therapy for coronavirus infection, Eur J Prev Cardiol,
doi:10.1177/2047487320919233Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of covid-19 -final report, N Engl J Med,
doi:10.1056/NEJMoa2007764Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19, N Engl J Med,
doi:10.1056/NEJMoa2016638Chan, Chan, Kao, To, Zheng et al., Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus, J Infect,
doi:10.1016/j.jinf.2013.09.029Charlson, Pompei, Ales, Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis,
doi:10.1016/0021-9681(87)90171-8Cheng, Cheng, Chen, Lin, Chuang et al., Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus, Antiviral Res,
doi:10.1016/j.antiviral.2014.12.011Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105938Ferrario, Jessup, Chappell, Averill, Brosnihan et al., Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Am J Physiol Renal Physiol,
doi:10.1152/ajprenal.00110.2010Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends,
doi:10.5582/bst.2020.01047Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Glowacka, Bertram, Muller, Allen, Soilleux et al., Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response, J Virol,
doi:10.1128/JVI.02232-10Gu, Xie, Li, Zhang, Lai et al., Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus, Sci Rep,
doi:10.1038/srep19840Hattermann, Müller, Nitsche, Wendt, Mantke et al., Susceptibility of different eukaryotic cell lines to SARS-coronavirus, Arch Virol,
doi:10.1007/s00705-004-0461-1Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell,
doi:10.1016/j.cell.2020.02.052Horby, Mafham, Linsell, Bell, Staplin et al., Effect of hydroxychloroquine in hospitalized patients with covid-19, N Engl J Med,
doi:10.1056/NEJMoa2022926Imam, Odish, Gill, Connor, Armstrong et al., Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States, J Intern Med,
doi:10.1111/joim.13119Kindrachuk, Ork, Hart, Mazur, Holbrook et al., Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis, Antimicrob Agents Chemother,
doi:10.1128/AAC.03659-14Kuba, Imai, Rao, Gao, Guo et al., A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury, Nat Med,
doi:10.1038/nm1267Li, Moore, Vasilieva, Sui, Wong et al., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature,
doi:10.1038/nature02145Madrid, Panchal, Warren, Shurtleff, Endsley et al., Evaluation of ebola virus inhibitors for drug repurposing, ACS Infect Dis,
doi:10.1021/acsinfecdis.5b00030Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, Med,
doi:10.1016/j.medj.2020.06.001Mancia, Rea, Ludergnani, Apolone, Corrao, Renin-angiotensin-aldosterone system blockers and the risk of Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2006923Matsuyama, Nagata, Shirato, Kawase, Takeda et al., Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2, J Virol,
doi:10.1128/JVI.01542-10Molina, Delaugerre, Goff, Lima, Ponscarme et al., No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, Med Mal Infect,
doi:10.1016/j.medmal.2020.03.006Mossel, Huang, Narayanan, Makino, Tesh et al., Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication, J Virol,
doi:10.1128/JVI.79.6.3846-3850.2005Onder, Rezza, Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA,
doi:10.1001/jama.2020.4683Pan, Peto, Henao-Restrepo, Preziosi, Sathiyamoorthy et al., Repurposed antiviral drugs for covid-19 -interim WHO solidarity trial results, N Engl J Med,
doi:10.1056/NEJMoa2023184Retallack, Lullo, Arias, Knopp, Laurie et al., Zika virus cell tropism in the developing human brain and inhibition by azithromycin, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.1618029113Reynolds, Adhikari, Pulgarin, Troxel, Iturrate et al., Reninangiotensin-aldosterone system inhibitors and risk of Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2008975Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA,
doi:10.1001/jama.2020.6775Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with inhospital mortality in patients with COVID-19 in New York State, JAMA,
doi:10.1001/jama.2020.8630Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, JAMA,
doi:10.1001/jama.2020.6019Stuart, Matching methods for causal inference: a review and a look forward, Stat Sci,
doi:10.1214/09-STS313Von Elm, Altman, Egger, Pocock, Gøtzsche et al., The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies, Ann Intern Med,
doi:10.7326/0003-4819-147-8-200710160-00010Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention, JAMA,
doi:10.1001/jama.2020.2648Zhang, Zhu, Cai, Lei, Qin et al., Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19, Circ Res,
doi:10.1161/CIRCRESAHA.120.317134Zimmermann, Ziesenitz, Curtis, Ritz, The immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms, Front Immunol,
doi:10.3389/fimmu.2018.00302
